The oral weight-loss drug introduced by Novo Nordisk this year in the U.S. is quickly being adopted.

Britain’s regulator approves a dose of up to 7.2 mg of semaglutide per week, up from 2.4 mg.

Jan 9 (Reuters) - Amazon Pharmacy said on Friday it now offers Novo Nordisk's Wegovy weight-loss pill through insurance plans as well as through a cash-pay option. Eligible customers with commercial ...

Novo Nordisk ( NVO +1.68%) was once the top player in the weight loss drug market. The company's medicine, Wegovy, ...

By Bhanvi Satija and Maggie Fick LONDON, Jan 16 (Reuters) - Novo Nordisk's Wegovy weight-loss pill has made an encouraging ...

Novo Nordisk announced Jan. 5 it will begin offering its Wegovy weight loss pill to self-paying patients in the United States, expanding access to the popular GLP-1 medication beyond injections.

Two weeks after securing approval from the U.S. Food and Drug Administration, a once-daily pill version of Novo Nordisk‘s popular GLP-1 weight loss drug Wegovy officially hit the market. In a Jan. 5 ...

Both companies now aim to win in the oral weight loss drug market.

The U.K.’s health regulator approved a higher dose of Novo Nordisk’s Wegovy weight-loss drug applicable to patients with a ...

Novo Nordisk’s wildly successful obesity medicine is now available as a pill, making it the first GLP-1 pill for weight loss in the United States. The pill is available in four doses and is cheaper ...

Wegovy’s oral version of its injectable weight-loss drug is seeing tremendous interest, Novo Nordisk executive Dave Moore told FOX Business on Friday.

The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss ...